FDA
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
-
-
-
-
-
-
-
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
-
-
-
-
-
-
-
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
-
-
-
-
-
-
-
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $49 at Scotiabank
-
-
-
-
-
-
-
BridgeBio Pharma's (BBIO) Acoramidis Receives Positive CHMP Opinion
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

